

# Caroline Gordon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2991074/caroline-gordon-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

15,295  
citations

57  
h-index

121  
g-index

229  
ext. papers

18,937  
ext. citations

5.2  
avg. IF

6.02  
L-index

#	Paper	IF	Citations
200	Will the feeling of abandonment remain? Persisting impacts of the Covid-19 pandemic on rheumatology patients and clinicians.. <i>Rheumatology</i> , <b>2022</b> ,	3.9	1
199	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9, e000584	4.6	0
198	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 3262-3267	3.9	2
197	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
196	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
195	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
194	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> ,	8	8
193	Telemedicine in rheumatology: A mixed methods study exploring acceptability, preferences and experiences among patients and clinicians. <i>Rheumatology</i> , <b>2021</b> ,	3.9	8
192	The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkaa072	1.1	11
191	Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1561-1567	4.7	1
190	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
189	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope. <i>Rheumatology</i> , <b>2021</b> , 60, 3565-3569	3.9	0
188	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 991-996	9.5	25
187	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
186	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
185	Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study. <i>Lupus</i> , <b>2021</b> , 30, 1492-1501	2.6	0
184	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 203	5.7	0

183	Medication decision-making and adherence in lupus: Patient-physician discordance and the impact of previous Adverse Medical Experiences <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
182	Constitutional symptoms and fatigue in systemic lupus erythematosus <b>2021</b> , 351-359		
181	Malignancies in systemic lupus erythematosus <b>2021</b> , 461-467		
180	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
179	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , <b>2021</b> , 60, 1480-1490	3.9	2
178	But you don't look sick! A qualitative analysis of the LUPUS UK online forum. <i>Rheumatology International</i> , <b>2021</b> , 41, 721-732	3.6	3
177	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE-data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 1474-1479	3.9	6
176	Malignancy risk and screening <b>2021</b> , 583-598		
175	COVID-19 and shielding: experiences of UK patients with lupus and related diseases. <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab003	1.1	3
174	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
173	Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review.. <i>Lupus</i> , <b>2021</b> , 9612033211050337	2.6	0
172	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
171	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
170	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa006	1.1	11
169	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2020</b> , 46, 533-550.	4	4
168	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
167	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
166	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15

165	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
164	Medications in pregnancy and breastfeeding. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 64, 68-76	4.6	8
163	Is it me? The impact of patient-physician interactions on lupus patients' psychological well-being, cognition and health-care-seeking behaviour. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa037	1.1	9
162	Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan. <i>Trials</i> , <b>2020</b> , 21, 652	2.8	3
161	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 874-881	4.7	19
160	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
159	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
158	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz021	1.1	2
157	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
156	Stratifying management of rheumatic disease for pregnancy and breastfeeding. <i>Nature Reviews Rheumatology</i> , <b>2019</b> , 15, 391-402	8.1	20
155	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 736-745	2.4	628
154	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
153	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
152	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 949-960	4.7	19
151	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
150	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000344	4.6	8
149	Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016. <i>Morbidity and Mortality Weekly Report</i> , <b>2019</b> , 68, 419-422	31.7	26
148	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015. <i>Morbidity and Mortality Weekly Report</i> , <b>2019</b> , 68, 819-824	31.7	5

147	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , <b>2019</b> , 9, e032569	3	21
146	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
145	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 729-735	2.4	20
144	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
143	Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 95-103	4.7	20
142	Obituary for Paul Bacon. <i>Rheumatology</i> , <b>2018</b> , 57, 943-945	3.9	
141	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 763-773	9.5	31
140	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
139	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
138	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
137	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , <b>2018</b> , 57, 14-18	3.9	23
136	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , <b>2018</b> , 57, 470-479	3.9	47
135	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.9	150
134	Epratuzumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 245-258	5.1	19
133	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , <b>2018</b> , 57, 1502-1503	3.9	7
132	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
131	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 554-561	2.4	175
130	Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 398	4.1	51

129	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2006-2017	9.5	78
128	The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1996-2005	9.5	80
127	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , <b>2017</b> , 56, 1041-1043	3.9	1
126	Prevalence of Mixed Connective Tissue Disease in a Population-Based Registry of American Indian/Alaska Native People in 2007. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1271-1275	4.7	8
125	Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Ataccept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 122-130	9.5	26
124	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 362-375	9.5	125
123	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
122	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
121	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , <b>2016</b> , 55, 957-67	3.9	57
120	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , <b>2016</b> , 61, 65-82	1	20
119	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 904-13	4.3	71
118	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16039	51.1	422
117	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. <i>Rheumatology</i> , <b>2016</b> , 55, 1693-7	3.9	251
116	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. <i>Rheumatology</i> , <b>2016</b> , 55, 1698-702	3.9	93
115	From BILAG to BILAG-based combined lupus assessment-30 years on. <i>Rheumatology</i> , <b>2016</b> , 55, 1357-63	3.9	9
114	Fertility and pregnancy in autoimmune rheumatic diseases. <i>Indian Journal of Rheumatology</i> , <b>2016</b> , 11, 115	0.5	
113	Malignancies in Systemic Lupus Erythematosus <b>2016</b> , 411-415		
112	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27

111	Constitutional Symptoms and Fatigue in Systemic Lupus Erythematosus <b>2016</b> , 317-324		1
110	Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 357-65	4.7	22
109	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1505-13	4.7	38
108	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
107	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 128-35	4.7	31
106	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2006-15	2.4	189
105	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
104	Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. <i>Rheumatology</i> , <b>2015</b> , 54, 836-43	3.9	64
103	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
102	Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e74-9	5.1	24
101	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 263-71	3.9	13
100	Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 369-78	9.5	262
99	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
98	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 958-67	2.4	388
97	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , <b>2014</b> , 53, 275-84	3.9	57
96	Interferon- $\beta$ -induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erythematosus monocytes. <i>Rheumatology</i> , <b>2014</b> , 53, 2249-58	3.9	32
95	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
94	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1167-76	4.7	43

93	Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 2494-502	9.5	75
92	Systemic lupus erythematosus and malignancies: a review article. <i>Rheumatic Disease Clinics of North America</i> , <b>2014</b> , 40, 497-506, viii	2.4	19
91	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , <b>2014</b> , 6, 1165-75	3.8	5
90	The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 357-68	9.5	205
89	Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. <i>BMJ Open</i> , <b>2014</b> , 4, e004081	3	48
88	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000034	4.6	15
87	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 183-90	2.4	205
86	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , <b>2014</b> , 53, 502-11	3.9	53
85	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 510-9	5.3	21
84	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
83	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
82	Rheumatic Disease <b>2013</b> , 1415-1440		
81	B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. <i>BioDrugs</i> , <b>2013</b> , 27, 85-95	7.9	31
80	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , <b>2013</b> , 13, 405-12	3.2	22
79	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2013</b> , 3,	3	14
78	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
77	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , <b>2013</b> , 52, 1313-22	3.9	98
76	Mortality in SLE <b>2013</b> , 666-675		2



75	In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 759-66	4.7	36
74	Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 1391-2	4.7	
73	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , <b>2013</b> , 52, 2292-301	3.9	58
72	Malignancies in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2013</b> , 8, 275-280	1.5	
71	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. <i>Rheumatology</i> , <b>2012</b> , 51, 1877-80	3.9	22
70	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , <b>2012</b> , 51, 2099-105	3.9	11
69	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1771-82	2.4	692
68	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
67	Refractory multisystem sarcoidosis responding to infliximab therapy. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1013-8	3.9	13
66	Systemic lupus and malignancies. <i>Current Opinion in Rheumatology</i> , <b>2012</b> , 24, 177-81	5.3	28
65	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
64	Co-morbidities in Systemic Lupus Erythematosus <b>2012</b> , 229-249		
63	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1068-72	4.7	28
62	Managing pregnancy in inflammatory rheumatological diseases. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, 206	5.7	34
61	Causes and management of infertility in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2011</b> , 50, 1551-8	3.9	54
60	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2011</b> , 50, 982-8	3.9	120
59	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , <b>2011</b> , 50, 657-64	3.9	91
58	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , <b>2010</b> , 49, 1665-9	3.9	84

57	The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2273-9	4.1	44
56	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , <b>2010</b> , 1, 163-75	4.9	39
55	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , <b>2010</b> , 49, 723-32	3.9	63
54	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 322-9	4.1	65
53	Systemic lupus erythematosus: clinical presentations. <i>Autoimmunity Reviews</i> , <b>2010</b> , 10, 43-5	13.6	82
52	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 211-21		106
51	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 222-33		866
50	Novel treatments for systemic lupus erythematosus. <i>Current Opinion in Investigational Drugs</i> , <b>2010</b> , 11, 1256-64		14
49	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , <b>2009</b> , 48, 1548-52	3.9	31
48	Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. <i>Rheumatology</i> , <b>2009</b> , 48, 1506-11	3.9	83
47	Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , <b>2009</b> , 48, 1451-4	3.9	144
46	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , <b>2009</b> , 48, 691-5	3.9	74
45	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 470-6	2.4	31
44	Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 457-67	5.3	31
43	Challenges of ethnicity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 549-61	5.3	23
42	Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline. <i>Musculoskeletal Care</i> , <b>2009</b> , 7, 210-8	1.6	7
41	Biologic therapy and pregnancy outcomes in women with rheumatic diseases. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 587-92		52
40	Population-based lupus registries: advancing our epidemiologic understanding. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1462-6		47

39	Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2009</b> , 5, 27-34	5.1	7
38	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1784-8		49
37	Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1789-95		15
36	Systemic lupus erythematosus in women: impact on family size. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 1656-60		22
35	Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. <i>Rheumatology</i> , <b>2008</b> , 47, 334-8	3.9	35
34	The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 64-70		51
33	Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1776-86		58
32	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 972-9		185
31	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 4113-9		76
30	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 569-70	2.4	1
29	Pregnancy and rheumatic diseases. <i>Rheumatology</i> , <b>2007</b> , 46, 1634-40	3.9	52
28	Ocular manifestations of systemic lupus erythematosus. <i>Rheumatology</i> , <b>2007</b> , 46, 1757-62	3.9	144
27	Constitutional Features of Systemic Lupus Erythematosus <b>2007</b> , 329-335		
26	Large vessel vasculitides. <i>Medicine</i> , <b>2006</b> , 34, 468-471	0.6	2
25	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2343-4		1
24	Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3300-5		77
23	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 892-9		81
22	Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R120	5.7	69

21	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, 209	5.7	373
20	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. <i>Arthritis Research and Therapy</i> , <b>2005</b> , 7, R784-95	5.7	332
19	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 685-708	5.3	217
18	Mycophenolate mofetil for remission induction in severe lupus nephritis. <i>Nephron Clinical Practice</i> , <b>2005</b> , 100, c92-100		24
17	Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 231-8	4.1	95
16	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2004</b> , 18, 359-393		40
15	Pregnancy and autoimmune diseases <b>2004</b> , 18, 359-359		12
14	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 2390-4	4.1	31
13	Lupus and zoster. <i>Lancet, The</i> , <b>2003</b> , 362, 616	4.0	4
12	A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves disease: Comment on the article by Rood et al. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 3109-10		18
11	Primary anti-phospholipid antibody syndrome (APS): current concepts. <i>Survey of Ophthalmology</i> , <b>2002</b> , 47, 215-38	6.1	70
10	Update on systemic lupus erythematosus: autoantibodies and apoptosis. <i>Clinical Medicine</i> , <b>2001</b> , 1, 10-4	1.9	23
9	The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 1410-8		54
8	Quality of life and economic evaluation in SLE clinical trials. <i>Lupus</i> , <b>1999</b> , 8, 645-54	2.6	34
7	Factors involved in the pathogenesis of neutrophilic vasculitis in MRL/Mp-lpr/lpr mice: a model for human microscopic angiitis. <i>Autoimmunity</i> , <b>1999</b> , 31, 133-45	3	4
6	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
5	The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 551-8		286
4	A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. <i>European Journal of Immunology</i> , <b>1994</b> , 24, 191-5	6.1	198

- 3 Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.  
*Drugs*, **1994**, 47, 259-85 12.1 6
- 2 Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.  
*Clinical Immunology and Immunopathology*, **1989**, 52, 421-34 134
- 1 Rheumatoid Arthritis/SLE267-281